PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients
Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled
Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide)
therapy along with standard supportive care in patients of acute ischemic stroke.